Full Press Release Details
Bioavailability Testing to Commence On Lexaria s
Patent-Pending Technology
Kelowna, BC / May 20, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) is pleased to announce it has engaged Absorption
Systems LP in the USA, to begin third party in vitro tests using a human
intestinal tissue model to evaluate the cannabidiol (CBD) permeability of its
patent-pending technology that infuses cannabinoid compounds within lipids.
The study will assess CBD permeability achieved with our
proprietary ViPova tea formulation at multiple sampling time points compared to
positive and negative controls under strict experimental conditions. In
vitro testing using human tissue models can be preferable to animal testing
since human cells can be used directly to provide species-specific permeability
Although we cannot know in advance the outcome of such tests,
the results have the potential to materially affect future outcomes for the
Company , said John Docherty, president of Lexaria. We have a wealth of
anecdotal evidence from our growing ViPova customer base extolling the marked
effects of our CBD-infused tea and we look forward to the outcome of this study
to help quantify this in detail.
It is generally accepted in pharmacological sectors that the
bioavailability of any active ingredient is one of the most important factors
determining its effects on the body. Enhanced bioavailability can be extremely
useful and is highly valued for any useful molecule, including CBD and
tetrahydrocannabinol (THC).
Lexaria expects to begin this testing in the near future and
will report results when they are available in due course, expected within the
Lexaria is a food sciences company focused on
the delivery of cannabinoid compounds procured from legal, agricultural hemp,
through gourmet foods based upon its proprietary infusion technologies.
legal CBD oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPovaTM has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com
About Absorption Systems
Absorption Systems assists
pharmaceutical, biotechnology and medical device companies in identifying and
overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity)
barriers in the development of drugs, biologics and medical devices. The
company's mission is to continually develop innovative research tools that can
be used to accurately predict human outcomes or to explain unanticipated human
outcomes when they occur. Absorption Systems, with facilities near Philadelphia,
PA, in San Diego, CA, and in Panama, serves customers throughout the world. For
information on the company's comprehensive contract services and applied
research programs, please visit www.absorption.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that the
medical marijuana, CBD sector, or alternative health businesses will provide any
benefit to Lexaria, or that the Company will experience any growth through
participation in these sectors. There is no assurance that any planned corporate
activity, business venture, or initiative will be pursued, or if pursued, will
be successful. There is no assurance that any cannabinoid-based product will
promote, assist, or maintain any beneficial human health conditions whatsoever.
There is no assurance that the cannabinoid/lipid infusion technology will
provide any increase in bioavailability to any individual person, nor that
bioavailability testing will produce any positive result. No statement herein
has been evaluated by the Food and Drug Administration (FDA).
ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.